2023
Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease
Ackley W, Dahl N, Park M. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2023, 30: 228-235. PMID: 37088525, DOI: 10.1053/j.akdh.2023.02.002.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseEnd-stage kidney diseaseKidney diseaseDominant polycystic kidney diseasePolycystic kidney diseaseRapid progressionMechanism-specific treatmentsChronic kidney diseaseFourth leading causeTreatment of patientsPharmacologic managementLeading causeKidney disordersFDA approvalDiseaseTolvaptanProgressionTreatmentRiskMorbidityPatientsPathogenesisTherapy
2022
The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, Hoge C, Oslin DW, Sall J, Wiechers IR, Williams S. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals Of Internal Medicine 2022, 175: 1440-1451. PMID: 36122380, DOI: 10.7326/m22-1603.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesMajor depressive disorderVeterans AffairsDepressive disorderPractice guidelinesDefense Clinical Practice GuidelineJoint clinical practice guidelineManagement of MDDTrustworthy clinical practice guidelinesUse of telemedicineMedicine's tenetsPharmacologic managementGuideline panelAlternative therapiesGRADE systemKey recommendationsPrior recommendationsClinical stakeholdersImportant new evidenceDisordersSelect recommendationsDepartmentGuidelinesManagementRecommendationsThe Primary Care Management of Headache: Synopsis of the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
Sico JJ, Macedo F, Lewis J, Spevak C, Vogsland R, Ford A, Skop K, Sall J. The Primary Care Management of Headache: Synopsis of the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Military Medicine 2022, 187: e1091-e1102. PMID: 35022782, DOI: 10.1093/milmed/usab490.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesPractice guidelinesDefense Clinical Practice GuidelineJoint clinical practice guidelineTrustworthy clinical practice guidelinesPractice Work GroupMedication overuse headachePrimary care managementPreferences of patientsGuideline development panelMedicine's tenetsPharmacologic managementRecommendations AssessmentOveruse headacheGuideline panelCare managementHeadacheDevelopment panelVeterans AffairsClinical stakeholdersPatientsGuidelinesIndividual needsDepartmentPrevention
2021
Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms
2020
Considerations Regarding the Pharmacological Management of Personality Disorders: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
Farhat L, Potenza M. Considerations Regarding the Pharmacological Management of Personality Disorders: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders. 2020, 517-520. DOI: 10.1017/9781108333931.089.Peer-Reviewed Original Research
2015
Medication Use and Metabolic Syndrome Among Overweight/Obese Patients With and Without Binge-Eating Disorder in a Primary Care Sample.
Barber JA, Schumann KP, Foran-Tuller KA, Islam LZ, Barnes RD. Medication Use and Metabolic Syndrome Among Overweight/Obese Patients With and Without Binge-Eating Disorder in a Primary Care Sample. The Primary Care Companion For CNS Disorders 2015, 17 PMID: 26835176, PMCID: PMC4732320, DOI: 10.4088/pcc.15m01816.Peer-Reviewed Original ResearchBody mass indexBinge-eating disorderOverweight/obese patientsMedication useMetabolic syndromeObese patientsWaist circumferencePrimary careHigher mean body mass indexNBO patientsMean body mass indexHigher Body Mass IndexFull metabolic syndromePoor metabolic healthCurrent medication useLarger waist circumferencePrimary care centersPrimary care sampleBinge Eating DisorderObjective measurementsPharmacologic managementMedication logMass indexMetabolic healthObese individuals
2012
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment options
2009
Hyperglycemia during the Immediate Period after Kidney Transplantation
Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, Hamawi K, Mulligan DC, Moss AA, Mekeel KL, Cosio FG, Cook CB. Hyperglycemia during the Immediate Period after Kidney Transplantation. Clinical Journal Of The American Society Of Nephrology 2009, 4: 853-859. PMID: 19339426, PMCID: PMC2666437, DOI: 10.2215/cjn.05471008.Peer-Reviewed Original ResearchConceptsNew-onset diabetesKidney transplantationPretransplantation diabetesHospital dischargeImmediate posttransplantation periodPrevalence of hypoglycemiaKidney transplant recipientsStress of surgeryShort-acting insulinEvidence of hyperglycemiaHospital stayImmunosuppression medicationsPharmacologic managementTransplant recipientsHospital phasePosttransplantation periodPharmacy databaseStudy cohortProspective studyTransient hyperglycemiaObservational studyMetabolic effectsHyperglycemiaPatientsTransplantationPharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia
Petrakis I. Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia. Contemporary Neuroscience 2009, 473-483. DOI: 10.1007/978-1-59745-197-0_25.Peer-Reviewed Original ResearchAlcohol use disorderOpioid antagonist naltrexoneUse disordersAntagonist naltrexoneTherapeutic optionsGeneral populationSchizoaffective disorderDevastating clinical disorderOpioid antagonist treatmentBest therapeutic optionGroup of patientsUse of naltrexoneSymptoms of psychosisNoncomorbid patientsPharmacologic managementAntagonist treatmentOpioid antagonistAlcohol use/dependenceComorbid schizophreniaClinical trialsPharmacotherapeutic effectsSchizophrenic patientsPatientsSide effectsCognitive symptoms
1992
Controlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder.
WOODS S, NAGY L, KOLESZAR A, KRYSTAL J, HENINGER G, CHAEY D. Controlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder. Current Opinion In Cardiology 1992, 7: 32. DOI: 10.1097/00001573-199202000-00006.Peer-Reviewed Original ResearchControlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder
WOODS S, NAGY L, KOLESZAR A, KRYSTAL J, HENINGER G, CHARNEY D. Controlled Trial of Alprazolam Supplementation During Imipramine Treatment of Panic Disorder. Journal Of Clinical Psychopharmacology 1992, 12: 32-38. PMID: 1552038, DOI: 10.1097/00004714-199202000-00006.Peer-Reviewed Original Research
1991
Idiopathic portal hypertension.
Orozco H, Takahashi T, García-Tsao G, Mercado M, Diliz H, Hernández-Ortiz J. Idiopathic portal hypertension. Revista De Investigación Clínica 1991, 43: 80-6. PMID: 1866503.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIdiopathic portal hypertensionPortal hypertensionHigh re-bleeding rateMain histopathologic findingsNoncirrhotic portal fibrosisObliterative portal venopathySmall portal veinsRe-bleeding rateIntra-abdominal infectionsLong-term prognosisUpper gastrointestinal tractHepatitis B virusEsophago-gastric varicesChronic sclerotherapyHepatoportal sclerosisIPH patientsPortal venopathyPharmacologic managementVariceal bleedingCirrhotic patientsImmunologic abnormalitiesPortal fibrosisLiver failurePeriportal fibrosisSuch patients
1984
HT-ATTENDING
Miller P, Black H. HT-ATTENDING. Journal Of Medical Systems 1984, 8: 181-187. PMID: 6548249, DOI: 10.1007/bf02224502.Peer-Reviewed Original ResearchMedical plan-analysis by computer: Critiquing the pharmacologic management of essential hypertension
Miller P, Black H. Medical plan-analysis by computer: Critiquing the pharmacologic management of essential hypertension. Journal Of Biomedical Informatics 1984, 17: 38-54. PMID: 6697700, DOI: 10.1016/0010-4809(84)90005-3.Peer-Reviewed Original ResearchConceptsArtificial intelligence techniquesPharmacologic managementEssential hypertensionInteractive paperIntelligence techniquesPatient careComputer systemsNew treatment modalitiesPhysician's management planHypertensive patientsTreatment modalitiesPhysicians' approachNew drugsCareHypertensionMedical practiceManagement errorsComputerPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply